181 related articles for article (PubMed ID: 19147777)
1. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Broniscer A; Baker SJ; Stewart CF; Merchant TE; Laningham FH; Schaiquevich P; Kocak M; Morris EB; Endersby R; Ellison DW; Gajjar A
Clin Cancer Res; 2009 Jan; 15(2):701-7. PubMed ID: 19147777
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
[TBL] [Abstract][Full Text] [Related]
4. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Geoerger B; Hargrave D; Thomas F; Ndiaye A; Frappaz D; Andreiuolo F; Varlet P; Aerts I; Riccardi R; Jaspan T; Chatelut E; Le Deley MC; Paoletti X; Saint-Rose C; Leblond P; Morland B; Gentet JC; Méresse V; Vassal G;
Neuro Oncol; 2011 Jan; 13(1):109-18. PubMed ID: 20974795
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
[TBL] [Abstract][Full Text] [Related]
6. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Christiansen SR; Broniscer A; Panetta JC; Stewart CF
Pharmacotherapy; 2009 Jul; 29(7):858-66. PubMed ID: 19558260
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
12. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Hughes AN; O'Brien ME; Petty WJ; Chick JB; Rankin E; Woll PJ; Dunlop D; Nicolson M; Boinpally R; Wolf J; Price A
J Clin Oncol; 2009 Mar; 27(8):1220-6. PubMed ID: 19164205
[TBL] [Abstract][Full Text] [Related]
13. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
White-Koning M; Civade E; Geoerger B; Thomas F; Le Deley MC; Hennebelle I; Delord JP; Chatelut E; Vassal G
Clin Cancer Res; 2011 Jul; 17(14):4862-71. PubMed ID: 21653689
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE
Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Macpherson IR; Poondru S; Simon GR; Gedrich R; Brock K; Hopkins CA; Stewart K; Stephens A; Evans TR
Eur J Cancer; 2013 Mar; 49(4):782-9. PubMed ID: 23099006
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
20. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
